Lymphedema

Home»Lymphedema
16 10, 2018

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint

2018-10-16T21:16:17+00:00

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PALO ALTO, Calif., October 16, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced Phase 2 ULTRA study results in primary and secondary [...]

Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint2018-10-16T21:16:17+00:00
4 01, 2018

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients

2018-01-04T15:07:20+00:00

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients - ULTRA Study Data Expected in Second Half 2018 PALO ALTO, Calif., January 4, 2018 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the [...]

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients2018-01-04T15:07:20+00:00
17 05, 2017

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema

2017-05-17T13:43:24+00:00

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema - Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif., May 17, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in [...]

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema2017-05-17T13:43:24+00:00
25 07, 2016

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema

2017-02-07T17:36:18+00:00

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema Novel first-in-class inhibitor of LTB4 production targeting disease modification PALO ALTO, Calif., July 25, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that the first [...]

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema2017-02-07T17:36:18+00:00
25 07, 2016

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema

2017-02-07T16:22:56+00:00

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema Novel first-in-class inhibitor of LTB4 production targeting disease modification PALO ALTO, Calif., July 25, 2016 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that [...]

Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 ULTRA Study of Ubenimex in Secondary Lymphedema2017-02-07T16:22:56+00:00
11 11, 2015

Eiger Bio Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University

2017-02-07T18:47:42+00:00

Eiger Bio Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University Novel Target Identified as Potential Therapeutic Approach for Lymphedema PALO ALTO, Calif., November 11, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today announced that it has acquired an exclusive license to technology for targeting effects of leukotriene B4 (LTB4) to reverse structural tissue changes [...]

Eiger Bio Announces Acquisition of Exclusive License to Lymphedema Program from Stanford University2017-02-07T18:47:42+00:00